Array-based Comparative Genomic Hybridisation In Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$314,773.00
Summary
Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. W ....Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. With exposure to cancer-causing agents such as cigarette smoke, parts of the lung may suffer permanent damage that increases the risk of lung cancer. Many of these changes include the genes in air passages and lung tissue. In this study, we will use the latest technology in genetics called gene chips to study changes in genes that affect the spread of lung cancer. These gene chips can study a vast number of genes at once. In particular, we will whether there is an abnormal number of copies of genes in the lung cancer. We hope that this research study will provide new information about the diagnosis and treatment of lung cancer.Read moreRead less
Genomic Profiling To Predict Lung Cancer Metastases
Funder
National Health and Medical Research Council
Funding Amount
$323,500.00
Summary
Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. W ....Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. In many cases, even with the best treatment available, the lung cancer spreads from where it starts, to other parts of the lung, chest and throughout the body. This eventually leads to death. We are interested in the factors that influence when and how lung cancer spreads. With exposure to cancer-causing agents such as cigarette smoke, parts of the lung may suffer permanent damage that increases the risk of lung cancer. Many of these changes include the genes in air passages and lung tissue. In this study, we will use the latest technology in genetics called gene chips to study changes in genes that affect the spread of lung cancer. These gene chips can study a vast number of genes at once. We hope that this research study will provide new information about the diagnosis and treatment of lung cancer.Read moreRead less
Deregulated Cytokine Signalling As A Molecular Bridge Linking The Pathogenesis Of Emphysema To Lung Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$524,820.00
Summary
Lung cancer is the most lethal form of cancer in Australia and worldwide. Although smokers with emphysema are at an increased risk of developing lung cancer, it is becoming apparent that emphysema can predispose to lung cancer independently of cigarette smoking, albeit by unknown mechanisms. Our aim is to combine smoke carcinogen and genetic mouse models of lung cancer with novel mouse strains displaying emphysema to identify the processes which link the pathogenesis of emphysema to lung cancer.
Population Health Modelling, With Applicationsto Asbestos-related Diseases, Cervical Cancer And Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
Population health modelling can be used to understand complex systems, through bringing together diverse data sources to answer questions of public health importance. We will apply modelling techniques to three public health areas, including: the effects of HPV testing on cervical cancer screening; the impact of the rapid uptake of PSA screening on prostate cancer incidence and mortality; and projections of the incidence of asbestos-related diseases.
Determining Patients And Doctors Preferences For Chemotherapy And Incorporating Them Into Clinical Decision-making
Funder
National Health and Medical Research Council
Funding Amount
$87,234.00
Summary
Chemotherapy improves survival in early lung cancer and advanced ovarian cancer but has significant side effects. Recent advances in chemotherapy have not been widely adopted because of differing opinions about whether the benefits of these treatments outweigh their harms. This research program will determine the benefits that patients and their doctors judge necessary to make these treatments worthwhile, and how best to incorporate this information into clinical discussions and decision-making.
Indwelling Pleural Catheter For Management Of Cancer-related Pleural Effusions
Funder
National Health and Medical Research Council
Funding Amount
$123,688.00
Summary
Most cancers can be complicated by fluid accumulation (effusion) in the (pleural) cavity between the lung and chest wall, causing significant breathlessness. Indwelling pleural catheter (IPC) is a new method that allows patients to drain the effusion outside the hospital and avoid further invasive interventions. This study aims to provide important information that will help guide use of IPC and manage its complications, especially infection, improve patient outcomes and save healthcare costs.
Identification, Validation And Functional Analysis Of Genes And MiRNAs Involved In Recurrent Non-small Cell Lung Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$104,664.00
Summary
Recurrence of lung cancer after treatment affects 20-85% of patients. Current prognostication tools are inaccurate and thus patients receive generic treatments. Our intention is to identify genes involved in recurrence of lung cancer. We foresee that this will translate to earlier identification of at-risk patients enabling individualised less toxic and more successful treatments. We also hope to better understand biology of lung cancer recurrence and discover new targets for treatment.
Role Of The LIM-only Protein LMO4 In Lung Development And Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$490,395.00
Summary
Lung cancer is the leading cause of death in cancer patients in Australia. Although treatments have improved in the past 10 years, new therapeutic strategies are eagerly awaited. Deregulation of molecules driving development of normal tissue is often observed in cancer. Our aim is to identify key regulators of lung development and lung repair after injury. We aim to evaluate the role of these molecules in the initiation and progression of lung cancer to identify new targets for therapies.
Understanding The Mechanisms Of Nanomedicine Absorption From The Lungs And The Application Of This Knowledge To Improving The Delivery Of Chemotherapeutic Nanomedicines Towards Primary And Secondary Lung Cancers
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
The administration of chemotherapeutic 'nanomedicines' via the lungs has the capacity to improve the specific delivery of toxic anti-cancer drugs specifically towards primary and metastatic lung cancers. This project aims to evaluate how nanomedicines are absorbed from the lungs after an inhaled dose, and how they can be best developed as inhaled chemotherapeutics for the treatment of lung cancers.